Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice

EMBO Molecular Medicine

Volumn 7, Issue 3, 2015, Pages 288-298

  Clemmensen, Christoffer ^a,b   Finan, Brian ^a,b   Fischer, Katrin ^a,b   Tom, Robby Zachariah ^a   Legutko, Beata ^a,b   Sehrer, Laura ^a,b   Heine, Daniela ^a,b   Grassl, Niklas ^a,b   Meyer, Carola W ^a,b   Henderson, Bart ^c   Hofmann, Susanna M ^a   Tschöp, Matthias H ^a,b   Van der Ploeg, Lex H T ^c   Müller, Timo D ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Rhythm Pharmaceuticals   (United States)

Author keywords

Diabetes; Glp 1r; Liraglutide; Mc4r; Obesity

Indexed keywords

CHOLESTEROL; GLUCOSE; LIRAGLUTIDE; SETMELANOTIDE; ALPHA INTERMEDIN; ANTIDIABETIC AGENT; BIM-22493; GLP1R PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; MELANOCORTIN 4 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG DOSE TITRATION; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; IN VIVO STUDY; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS; DRUG POTENTIATION; MOUSE MUTANT; OBESITY; TREATMENT OUTCOME;

ALPHA-MSH; ANIMALS; DIABETES MELLITUS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MICE, OBESE; OBESITY; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 84929837322     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404508     Document Type: Article

References (36)

1. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME, Group NNS (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374: 1606-1616
2. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T, Ferreira M, Tang V, McGovern RA, Kenny CD et al (2005) Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123: 493-505
3. Bluher S, Ziotopoulou M, Bullen JW Jr, Moschos SJ, Ungsunan L, Kokkotou E, Maratos-Flier E, Mantzoros CS (2004) Responsiveness to peripherally administered melanocortins in lean and obese mice. Diabetes 53: 82-90
4. Castro MG, Morrison E (1997) Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Crit Rev Neurobiol 11: 35-57
5. Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, Lim CT, Parvizi N, Hussein M, Chambers ES et al (2014) Co-infusion of low-dose glucagon-like peptide-1 (GLP-1) and glucagon in man results in a reduction in food intake. Diabetes 63: 3711-3720
6. Chen AS, Metzger JM, Trumbauer ME, Guan XM, Yu H, Frazier EG, Marsh DJ, Forrest MJ, Gopal-Truter S, Fisher J et al (2000) Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res 9: 145-154
7. Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, Kuchler D, Sehrer L, Ograjsek T, Hofmann SM, Schriever SC et al (2014) GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63: 1422-1427
8. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5: 749-757
9. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705
10. Fani L, Bak S, Delhanty P, van Rossum EF, van den Akker EL (2014) The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int J Obes 38: 163-169
11. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348: 1085-1095
12. Finan B, Yang B, Ottaway N, Stemmer K, Muller TD, Yi CX, Habegger K, Schriever SC, Garcia-Caceres C, Kabra DG et al (2012) Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 18: 1847-1856
13. Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C et al (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5: 209ra151
14. Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21: 27-36
15. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509
16. Garber AJ (2011) Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 34(Suppl 2): S279-S284
17. Greenway FL, Bray GA (2010) Combination drugs for treating obesity. Curr DiabRep 10: 108-115
18. Hofmann SM, Perez-Tilve D, Greer TM, Coburn BA, Grant E, Basford JE, Tschop MH, Hui DY (2008) Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes 57: 5-12
19. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD et al (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141
20. Kievit P, Halem H, Marks DL, Dong JZ, Glavas MM, Sinnayah P, Pranger L, Cowley MA, Grove KL, Culler MD (2013) Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 62: 490-497
21. Kopelman PG (2000) Obesity as a medical problem. Nature 404: 635-643
22. Madsbad S (2014) The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 16: 9-21
23. McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW (2000) Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. Am J Physiol Regul Integr Comp Physiol 279: R695-R703
24. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8: 728-742
25. Muller TD, Sullivan LM, Habegger K, Yi CX, Kabra D, Grant E, Ottaway N, Krishna R, Holland J, Hembree J et al (2012) Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 18: 383-393
26. Obici S, Feng Z, Tan J, Liu L, Karkanias G, Rossetti L (2001) Central melanocortin receptors regulate insulin action. J Clin Investig 108: 1079-1085
27. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G et al (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58: 2258-2266
28. Rodgers RJ, Tschop MH, Wilding JP (2012) Anti-obesity drugs: past, present and future. Dis Model Mech 5: 621-626
29. Rueda-Clausen CF, Padwal RS, Sharma AM (2013) New pharmacological approaches for obesity management. Nat Rev Endocrinol 9: 467-478
30. Sadry SA, Drucker DJ (2013) Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol 9: 425-433
31. Scheen AJ, Van Gaal LF (2014) Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2: 911-922
32. Tao YX (2010) The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev 31: 506-543
33. Tschop MH, Speakman JR, Arch JR, Auwerx J, Bruning JC, Chan L, Eckel RH, Farese RV Jr, Galgani JE, Hambly C et al (2012) A guide to analysis of mouse energy metabolism. Nat Methods 9: 57-63
34. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344: d7771
35. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M (2011) Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378: 815-825
36. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S (1998) A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20: 111-112